Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain

Abstract Background Microglia pyroptosis, a newly identified form of inflammatory cell death, is involved in the development of neuropathic pain (NP). Botulinum toxin type A (BTX-A) has been shown to be effective in relieving NP, but the mechanisms involved have not been clarified. Methods A mice mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheng Tian, Lanxiang Wu, Heqing Zheng, Zhijuan Cheng, Jingjing Liu, Mingxu Liu, Xinping Yu, Jianglong Tu, Wei Wu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:The Journal of Headache and Pain
Subjects:
Online Access:https://doi.org/10.1186/s10194-025-02109-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234892441780224
author Sheng Tian
Lanxiang Wu
Heqing Zheng
Zhijuan Cheng
Jingjing Liu
Mingxu Liu
Xinping Yu
Jianglong Tu
Wei Wu
author_facet Sheng Tian
Lanxiang Wu
Heqing Zheng
Zhijuan Cheng
Jingjing Liu
Mingxu Liu
Xinping Yu
Jianglong Tu
Wei Wu
author_sort Sheng Tian
collection DOAJ
description Abstract Background Microglia pyroptosis, a newly identified form of inflammatory cell death, is involved in the development of neuropathic pain (NP). Botulinum toxin type A (BTX-A) has been shown to be effective in relieving NP, but the mechanisms involved have not been clarified. Methods A mice model of NP was established with chronic constriction injury (CCI) method. The expression levels of key molecules and the extent of microglia pyroptosis were assessed using RT-qPCR, western blot, ELISA and immunofluorescence. Moreover, lipopolysaccharide (LPS) was used in vitro to induce pyroptosis of microglia to explore the potential molecular mechanisms of BTX-A. Result In a mice model of NP, BTX-A administration increased the pain threshold and decreased the Cblb protein expression level, consistent with the results of in vitro experiments. Functional experiments and mouse models were respectively used to evaluate the severity of microglia pyroptosis. The results showed that BTX-A inhibited microglia pyroptosis through Cblb protein. Subsequently, mass spectrometry (MS) analysis and immunoprecipitation were conducted to identify proteins interacting with Cblb. The results identified Pdlim1 was a potential interacting partner of Cblb, which regulats the ubiquitination of Pdlim1. Mechanically, Cblb binds to the PDZ and LIM domains of Pdlim1 and then targets Pdlim1 at K244 for ubiquitination and proteasome-mediated degradation. Pdlim1 knockdown lentiviral plasmid was constructed and stable Pdlim1 knockdown microglial cell lines were established for rescue experiments. The results demonstrated that BTX-A suppresses microglia pyroptosis via Pdlim1/NF-κB signaling axis. Finally, intrathecal injection of adeno-associated virus overexpressing Cblb was used in rescue experiments. The results confirmed that BTX-A attenuates neuropathic pain via the Cblb/Pdlim1/NF-kB signaling axis. Conclusions This study demonstrates that BTX-A suppresses the activity of Cblb, thereby reducing Pdlim1 protein degradation, inhibiting the NF-kB pathway, and ultimately mitigating microglia pyroptosis. Our findings suggest that Cblb could serve as a novel therapeutic target for BTX-A in the treatment of NP.
format Article
id doaj-art-0d006aeaa8c74accaf6cf7c79342cf85
institution Kabale University
issn 1129-2377
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series The Journal of Headache and Pain
spelling doaj-art-0d006aeaa8c74accaf6cf7c79342cf852025-08-20T04:03:00ZengBMCThe Journal of Headache and Pain1129-23772025-07-0126111910.1186/s10194-025-02109-wBotulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic painSheng Tian0Lanxiang Wu1Heqing Zheng2Zhijuan Cheng3Jingjing Liu4Mingxu Liu5Xinping Yu6Jianglong Tu7Wei Wu8Department of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, Yingtan City People’s HospitalDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Neurology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityAbstract Background Microglia pyroptosis, a newly identified form of inflammatory cell death, is involved in the development of neuropathic pain (NP). Botulinum toxin type A (BTX-A) has been shown to be effective in relieving NP, but the mechanisms involved have not been clarified. Methods A mice model of NP was established with chronic constriction injury (CCI) method. The expression levels of key molecules and the extent of microglia pyroptosis were assessed using RT-qPCR, western blot, ELISA and immunofluorescence. Moreover, lipopolysaccharide (LPS) was used in vitro to induce pyroptosis of microglia to explore the potential molecular mechanisms of BTX-A. Result In a mice model of NP, BTX-A administration increased the pain threshold and decreased the Cblb protein expression level, consistent with the results of in vitro experiments. Functional experiments and mouse models were respectively used to evaluate the severity of microglia pyroptosis. The results showed that BTX-A inhibited microglia pyroptosis through Cblb protein. Subsequently, mass spectrometry (MS) analysis and immunoprecipitation were conducted to identify proteins interacting with Cblb. The results identified Pdlim1 was a potential interacting partner of Cblb, which regulats the ubiquitination of Pdlim1. Mechanically, Cblb binds to the PDZ and LIM domains of Pdlim1 and then targets Pdlim1 at K244 for ubiquitination and proteasome-mediated degradation. Pdlim1 knockdown lentiviral plasmid was constructed and stable Pdlim1 knockdown microglial cell lines were established for rescue experiments. The results demonstrated that BTX-A suppresses microglia pyroptosis via Pdlim1/NF-κB signaling axis. Finally, intrathecal injection of adeno-associated virus overexpressing Cblb was used in rescue experiments. The results confirmed that BTX-A attenuates neuropathic pain via the Cblb/Pdlim1/NF-kB signaling axis. Conclusions This study demonstrates that BTX-A suppresses the activity of Cblb, thereby reducing Pdlim1 protein degradation, inhibiting the NF-kB pathway, and ultimately mitigating microglia pyroptosis. Our findings suggest that Cblb could serve as a novel therapeutic target for BTX-A in the treatment of NP.https://doi.org/10.1186/s10194-025-02109-wBTX-ANeuropathic painCblbMicroglia pyroptosis
spellingShingle Sheng Tian
Lanxiang Wu
Heqing Zheng
Zhijuan Cheng
Jingjing Liu
Mingxu Liu
Xinping Yu
Jianglong Tu
Wei Wu
Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain
The Journal of Headache and Pain
BTX-A
Neuropathic pain
Cblb
Microglia pyroptosis
title Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain
title_full Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain
title_fullStr Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain
title_full_unstemmed Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain
title_short Botulinum toxin type A inhibits microglia pyroptosis by suppressing Cblb-mediated degradation of Pdlim1 to attenuate neuropathic pain
title_sort botulinum toxin type a inhibits microglia pyroptosis by suppressing cblb mediated degradation of pdlim1 to attenuate neuropathic pain
topic BTX-A
Neuropathic pain
Cblb
Microglia pyroptosis
url https://doi.org/10.1186/s10194-025-02109-w
work_keys_str_mv AT shengtian botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT lanxiangwu botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT heqingzheng botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT zhijuancheng botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT jingjingliu botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT mingxuliu botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT xinpingyu botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT jianglongtu botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain
AT weiwu botulinumtoxintypeainhibitsmicrogliapyroptosisbysuppressingcblbmediateddegradationofpdlim1toattenuateneuropathicpain